Table 2. Mean QALYs and costs (in euro’s) per patient over the 1-year follow-up period.
| Ceftriaxone +doxycycline (N = 82) | Ceftriaxone + clarithromycin-hydroxychloroquine (N = 93) | Ceftriaxone +placebo (N = 96) | P valuea | ||||
|---|---|---|---|---|---|---|---|
| Mean | (95% CI) | Mean | (95% CI) | Mean | (95% CI) | ||
| QALYs | 0.82 | (0.77–0.88) | 0.81 | (0.76–0.88) | 0.81 | (0.76–0.86) | 0.96 |
| Direct costs within healthcare | |||||||
| Antibiotic therapyb | 2254 | (-) | 2282 | (-) | 2211 | (-) | - |
| Pain medication | 36 | (23–52) | 22 | (16–29) | 33 | (22–45) | 0.24 |
| Healthcare consumption | 1802 | (1211–2517) | 2324 | (1508–3286) | 3296 | (1675–5521) | 0.35 |
| Direct costs outside healthcare Travel expenses | 104 | (66–148) | 58 | (39–75) | 83 | (51–127) | 0.23 |
| Indirect costs Productivity losses | 7667 | (4466–12039) | 7858 | (5450–10667) | 9392 | (6941–12270) | 0.70 |
| Total costs | 11995 | (8823–15670) | 12202 | (9572–15253) | 15249 | (11294–19781) | 0.28 |
a Bootstrapped ANCOVA corrected for baseline value and paid work.
b Costs of the antibiotic therapy were standardized.
QALY, quality-adjusted life year.